Cite
HARVARD Citation
Engebraaten, O. et al. (2012). Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial. ISRN oncology. p. . [Online].